Entrada Therapeutics (NASDAQ:TRDA) Insider Sells $398,708.73 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) insider Natarajan Sethuraman sold 25,907 shares of the business’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $15.39, for a total value of $398,708.73. Following the completion of the transaction, the insider directly owned 216,317 shares in the company, valued at approximately $3,329,118.63. This represents a 10.70% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Entrada Therapeutics Price Performance

Entrada Therapeutics stock traded up $1.29 on Monday, reaching $15.79. The company’s stock had a trading volume of 426,082 shares, compared to its average volume of 173,892. The business’s fifty day moving average price is $12.72 and its 200 day moving average price is $10.75. Entrada Therapeutics, Inc. has a twelve month low of $4.93 and a twelve month high of $16.00.

Entrada Therapeutics (NASDAQ:TRDA) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.94) EPS for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.38. The company had revenue of $1.30 million for the quarter, compared to analyst estimates of $7.41 million. Entrada Therapeutics had a negative return on equity of 39.83% and a negative net margin of 565.48%. Equities research analysts forecast that Entrada Therapeutics, Inc. will post -4.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

TRDA has been the subject of a number of recent research reports. Wall Street Zen downgraded Entrada Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Weiss Ratings restated a “sell (d)” rating on shares of Entrada Therapeutics in a research report on Friday, March 27th. Cantor Fitzgerald initiated coverage on Entrada Therapeutics in a research report on Wednesday, April 1st. They set an “overweight” rating for the company. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Entrada Therapeutics in a research report on Wednesday, February 18th. Finally, Oppenheimer boosted their target price on Entrada Therapeutics from $21.00 to $23.00 and gave the stock an “outperform” rating in a research report on Monday, April 6th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $19.00.

Institutional Investors Weigh In On Entrada Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Baker BROS. Advisors LP increased its holdings in Entrada Therapeutics by 4.3% in the fourth quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company’s stock valued at $52,148,000 after purchasing an additional 206,911 shares during the last quarter. Wellington Management Group LLP increased its holdings in Entrada Therapeutics by 9.5% in the fourth quarter. Wellington Management Group LLP now owns 1,044,758 shares of the company’s stock valued at $10,740,000 after purchasing an additional 90,339 shares during the last quarter. Millennium Management LLC increased its holdings in Entrada Therapeutics by 391.2% in the third quarter. Millennium Management LLC now owns 836,609 shares of the company’s stock valued at $4,852,000 after purchasing an additional 666,287 shares during the last quarter. Geode Capital Management LLC increased its holdings in Entrada Therapeutics by 7.2% in the second quarter. Geode Capital Management LLC now owns 631,554 shares of the company’s stock valued at $4,245,000 after purchasing an additional 42,479 shares during the last quarter. Finally, State Street Corp increased its holdings in Entrada Therapeutics by 2.0% in the fourth quarter. State Street Corp now owns 508,789 shares of the company’s stock valued at $5,230,000 after purchasing an additional 10,174 shares during the last quarter. Institutional investors own 86.39% of the company’s stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.